Investrend Research Announces Investmnet Opinion On TFC Enterprises, Inc., Paradigm Medical Industries, HPSC, Inc. and Praxis Pharmaceutical.Business Editors NOTE TO EDITORS: The following is an investment opinion issued by Investrend Research, Inc. NEW YORK--(BUSINESS WIRE)--April 6, 2001 Investrend Research analysts this week issued research reports or research notes on the following companies under its continuing analyst research program. The complete report or research note, as well as other current and previously published research reports and analyst notes on all companies we cover, can be accessed at no cost at www.investrend.com. Investrend also provides periodic commentaries and summaries of its research by email, with signup on our website above. TFC Enterprises, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : TFCE TFCE Tracy Farmer Center for the Environment (University of Kentucky) ) By Richard W. West Richard W. West was the mayor of Newport News, Virginia from 1932 to 1936. Preceded by Harry Reyner Mayor of Newport News 1932–1936 Succeeded by B. G. James , CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. TFC Enterprises Receives $60 Million In Latest Securitization and Extends $100 Million Prime Facility The latest term securitization agreement placed $80 million of automobile receivables-backed securities at a gross spread of over 13%, and the Company announced extension of its $100 million prime credit facility agreement through January 1, 2002. We discuss the TFC Enterprises reported fourth quarter and results for the year ended December 31, 2000, and the outlook for the stock at current levels. Paradigm Medical Industries (NASDAQ: PMED PMED Primary and Mass Education Division ) By Sherry Grisewood, CFA Paradigm Filed A Notification Of Late Filing With The SEC For Its Year 2000 10K We discuss the share outlook of the Company whose flagship product, the Photon Laser cataract surgical system, currently awaiting final FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval, has the potential to fundamentally change cataract surgery. We were not surprised that the company made this Notification of Late Filing, considering the acquisitions consummated this year. As the Company gears sales to its next generation surgical Workstation systems, we expect to see additional one-time inventory write-down charges. HPSC HPSC High Performance Scientific Computing HPSC High Performance Super Computer HPSC High Pressure Steam Chest HPSC Houston Product Support Center (Boeing) HPSC Human Performance Systems Center , Inc. (AMEX AMEX See: American Stock Exchange : HDR) By Richard W. West, CFA Strong Initial Buy Recommendation Issued For HPSC, Inc Among the investment considerations noted are: HPSC earnings per share increased at an average annual growth rate of approximately 45% in the periods of FY1995 to FY1999. Adjusting announced 2000 results for costs of its $527 million year-end securitization, this trend continued. The stock sells at a 35% discount from book value for this company that is in a premium category. Praxis Pharmaceutical (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : PRXX) by Randall D. Lewis, CFA Praxis Pharmaceutical Begins Production for Pre-Clinical Studies The market targeted by the Company for the treatment of inflammatory conditions exceeds $10 billion, and existing therapeutics are poor compared with the potential available to Praxis. The company's unique therapy has the potential to essentially eliminate side effects for a broad range of illnesses. It has placed a production order to begin pre-clinical studies. All reports and research notes are issued under the Public Analysis & Review (PAR) program of Investrend Research. Anyone, including a company, may enroll a company for annual coverage. PAR reports are performed on behalf of the public, and are not a service to any company. PAR analysts, primarily CFAs, are responsible only to the public. PAR analysts are paid in advance to eliminate pecuniary interests and insure independence. PAR annual enrollment fees are $19,700 per annum. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion